| Revenue growth | 2% YoY for FY25-26. |
|---|---|
| Margins | EBITDA margin expanded 290bps YoY to 34.3% in FY26. |
| Demand visibility | Strong momentum in innovative portfolio; Oncology and Respiratory driving growth. |
| Management confidence | High, citing profitable growth trajectory and margin expansion. |
Growth
FY26 Revenue grew 2% to ₹3790cr; EBITDA grew 11% to ₹1300cr; PAT (pre-exceptional) grew 10% to ₹1010cr.
Outlook
Final dividend declared at ₹57/share; focusing on unlocking growth through CVMD opportunity and new oncology launches.
Risks
Pharma sales softened by supply constraints; Vaccines shipment phasing impacted Q4 headline sales growth.
Earnings Call filed with BSE, NSE: GLAXO. Summary written with AI assistance from the document.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,755.00
- Market cap
- ₹46,671 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 43.7×Sector 47.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals issued a corrigendum for its August 3, 2026, postal ballot notice, correcting a typographical error in a reported salary figure.
GlaxoSmithKline Pharmaceuticals Price Movement Clarification
GlaxoSmithKline Pharmaceuticals clarified that recent trading volume increases are purely market-driven. The company confirmed all material disclosures have been made according to SEBI regulations.
GlaxoSmithKline Pharmaceuticals Business Update
GlaxoSmithKline Pharmaceuticals received an income tax refund intimation of Rs 4.99 Crore for the assessment year 2025-2026.
- Value
- ₹4.99 Cr
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals has issued a Postal Ballot notice for shareholder approval. The resolutions involve appointing Karine J F Natland and re-appointing Bhushan Akshikar as Managing Director.
GlaxoSmithKline Pharmaceuticals Legal & Regulatory
GlaxoSmithKline Pharmaceuticals received a ₹52.00 Crore tax refund plus ₹42.09 Crore interest income following a favorable CIT-Appeal order for assessment year 1984-85.
- Value
- ₹94.09 Cr